Literature DB >> 19931447

Visualizing cancer and immune cell function with metabolic positron emission tomography.

Rachel E Laing1, Evan Nair-Gill, Owen N Witte, Caius G Radu.   

Abstract

Cancer cells and immune cells modulate their metabolism according to specific needs during cancer progression and immune responses. The ability to measure cellular metabolic function in vivo would enable the evaluation of tumors and their response to therapy and also the effectiveness of cellular immune responses to cancer. Positron emission tomography (PET) is a highly sensitive clinical imaging modality that enables whole-body, quantitative measurements of tissue biochemical function. Here, we review work using PET probes for specific metabolic pathways to measure cell function in cancer and immunity. We focus on the use of probes for glycolysis and nucleoside salvage and then discuss the development of new metabolic probes that visualize distinct parameters of cell function during disease. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19931447      PMCID： PMC3799818          DOI： 10.1016/j.gde.2009.10.008

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN： 0959-437X            Impact factor:   5.578


  58 in total

1.  Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis.

Authors:  Caius G Radu; Chengyi J Shu; Stephanie M Shelly; Michael E Phelps; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-29       Impact factor: 11.205

2.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

3.  Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma.

Authors:  J D Wagner; D Schauwecker; G Hutchins; J J Coleman
Journal:  J Surg Oncol       Date:  1997-03       Impact factor: 3.454

Review 4.  PET: the merging of biology and imaging into molecular imaging.

Authors:  M E Phelps
Journal:  J Nucl Med       Date:  2000-04       Impact factor: 10.057

5.  Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.

Authors:  Aren van Waarde; David C P Cobben; Albert J H Suurmeijer; Bram Maas; Willem Vaalburg; Erik F J de Vries; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

6.  FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.

Authors:  Matthias R Benz; Johannes Czernin; Martin S Allen-Auerbach; William D Tap; Sarah M Dry; David Elashoff; Kira Chow; Vladimir Evilevitch; Jeff J Eckardt; Michael E Phelps; Wolfgang A Weber; Fritz C Eilber
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

Review 7.  Molecular-genetic imaging based on reporter gene expression.

Authors:  Joo Hyun Kang; June-Key Chung
Journal:  J Nucl Med       Date:  2008-06       Impact factor: 10.057

8.  Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.

Authors:  E Pelosi; P Pregno; D Penna; D Deandreis; A Chiappella; G Limerutti; U Vitolo; M Mancini; G Bisi; E Gallo
Journal:  Radiol Med       Date:  2008-04-14       Impact factor: 3.469

9.  Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors.

Authors:  Matthias R Benz; Vladimir Evilevitch; Martin S Allen-Auerbach; Fritz C Eilber; Michael E Phelps; Johannes Czernin; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2008-06-13       Impact factor: 10.057

10.  Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog.

Authors:  Caius G Radu; Chengyi J Shu; Evan Nair-Gill; Stephanie M Shelly; Jorge R Barrio; Nagichettiar Satyamurthy; Michael E Phelps; Owen N Witte
Journal:  Nat Med       Date:  2008-06-08       Impact factor: 53.440
View more
  14 in total

1.  18F-FAC PET Selectively Images Liver-Infiltrating CD4 and CD8 T Cells in a Mouse Model of Autoimmune Hepatitis.

Authors:  Jessica R Salas; Bao Ying Chen; Alicia Wong; Donghui Cheng; John S Van Arnam; Owen N Witte; Peter M Clark
Journal:  J Nucl Med       Date:  2018-04-26       Impact factor: 10.057

Review 2.  Noninvasive PET Imaging of T cells.

Authors:  Weijun Wei; Dawei Jiang; Emily B Ehlerding; Quanyong Luo; Weibo Cai
Journal:  Trends Cancer       Date:  2018-04-17

Review 3.  Advances in PET Detection of the Antitumor T Cell Response.

Authors:  M N McCracken; R Tavaré; O N Witte; A M Wu
Journal:  Adv Immunol       Date:  2016-04-05       Impact factor: 3.543

4.  Imaging activated T cells predicts response to cancer vaccines.

Authors:  Israt S Alam; Aaron T Mayer; Idit Sagiv-Barfi; Kezheng Wang; Ophir Vermesh; Debra K Czerwinski; Emily M Johnson; Michelle L James; Ronald Levy; Sanjiv S Gambhir
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

5.  Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo.

Authors:  Richard Tavaré; Melissa N McCracken; Kirstin A Zettlitz; Scott M Knowles; Felix B Salazar; Tove Olafsen; Owen N Witte; Anna M Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-03       Impact factor: 11.205

Review 6.  Imaging for Response Assessment in Radiation Oncology: Current and Emerging Techniques.

Authors:  Sonja Stieb; Kendall Kiser; Lisanne van Dijk; Nadia Roxanne Livingstone; Hesham Elhalawani; Baher Elgohari; Brigid McDonald; Juan Ventura; Abdallah Sherif Radwan Mohamed; Clifton David Fuller
Journal:  Hematol Oncol Clin North Am       Date:  2019-10-31       Impact factor: 3.722

7.  CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols.

Authors:  Anna M Wu; Katherine W Ferrara; Jai Woong Seo; Richard Tavaré; Lisa M Mahakian; Matthew T Silvestrini; Sarah Tam; Elizabeth S Ingham; Felix B Salazar; Alexander D Borowsky
Journal:  Clin Cancer Res       Date:  2018-07-02       Impact factor: 12.531

8.  Dissecting the target leukocyte subpopulations of clinically relevant inflammation radiopharmaceuticals.

Authors:  Tobias Borchert; Laura Beitar; Laura B N Langer; Andras Polyak; Hans-Jürgen Wester; Tobias L Ross; Denise Hilfiker-Kleiner; Frank M Bengel; James T Thackeray
Journal:  J Nucl Cardiol       Date:  2019-10-28       Impact factor: 5.952

9.  Metabolic radiolabeling and in vivo PET imaging of cytotoxic T lymphocytes to guide combination adoptive cell transfer cancer therapy.

Authors:  Dehua Lu; Yanpu Wang; Ting Zhang; Feng Wang; Kui Li; Shixin Zhou; Hua Zhu; Zhi Yang; Zhaofei Liu
Journal:  J Nanobiotechnology       Date:  2021-06-10       Impact factor: 10.435

10.  Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring.

Authors:  Fuqiang Shao; Yu Long; Hao Ji; Dawei Jiang; Ping Lei; Xiaoli Lan
Journal:  Theranostics       Date:  2021-05-03       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.